Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Prostate Cancer
97%
Diffuse Large B-Cell Lymphoma
84%
Malignant Neoplasm
71%
Overall Survival
69%
Cohort Analysis
60%
Bone Metastasis
57%
Gallium 68
56%
Neoplasm
53%
Bone Scintigraphy
51%
Systematic Review
51%
Diseases
48%
Biological Marker
48%
Pancreas Cancer
45%
Cancer
36%
Diagnosis
35%
Fluorine-18
29%
Hazard Ratio
29%
Colorectal Cancer
27%
Lung Cancer
27%
Non Small Cell Lung Cancer
27%
Acute Myeloid Leukemia
24%
Multiple Myeloma
23%
Metastatic Carcinoma
23%
Clinical Trial
23%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
22%
Venous Thromboembolism
21%
Immune Checkpoint Inhibitor
21%
Positron Emission Tomography
21%
Minimal Residual Disease
21%
Biopsy
20%
Pancreas Adenocarcinoma
20%
Radiation Therapy
20%
Computer Assisted Tomography
19%
Fluorodeoxyglucose F 18
19%
Progression Free Survival
18%
Prostate Specific Membrane Antigen
18%
Cancer Risk
17%
Prospective Study
17%
Rituximab
16%
Pleura Mesothelioma
16%
Hodgkin's Lymphoma
16%
International Prognostic Index
15%
Gene Expression
15%
Non-Hodgkin Lymphoma
15%
Positron Emission Tomography
15%
Immunotherapy
15%
Proportional Hazards Model
14%
B Cell
14%
Cancer Staging
14%
Quality of Life
14%
Promoter Region
14%
Diagnostic Accuracy
14%
Oncology
13%
Recurrent Disease
13%
Personalized Medicine
13%
Rectum Cancer
13%
Randomized Controlled Trial
12%
Gemcitabine
12%
Prostatectomy
12%
Biochemical Recurrence
12%
Recurrence Risk
12%
Drug Megadose
12%
Adjuvant Chemotherapy
12%
Circulating Tumor DNA
11%
Vincristine
11%
Treatment Response
11%
Prognostic Factor
11%
BRCA1
11%
Cancer Therapy
11%
Magnetic Resonance Imaging
11%
Low Drug Dose
11%
Hematological Cancer
11%
microRNA
10%
Thyroid Gland
10%
Krukenberg Tumor
10%
Follicular Lymphoma
10%
Population
10%
BRCA2
10%
Cell-Free DNA
10%
Symptom
10%
Mortality
9%
Cancer Treatment
9%
Prevalence
9%
Incidental Finding
9%
Neuroendocrine Tumor
9%
Colonoscopy
9%
Irreversible Electroporation
9%
Ovarian Cancer
9%
Rheumatoid Arthritis
9%
Single Photon Emission Computed Tomography-Computed Tomography
9%
Second Cancer
9%
Myeloma
9%
Smoking
9%
Cyclophosphamide
8%
Combination Chemotherapy
8%
Fluorodeoxyglucose
8%
Doxorubicin
8%
Odds Ratio
8%
Supportive Care
7%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
58%
Malignant Neoplasm
50%
Chemotherapy
48%
Cohort Study
40%
Disease
36%
Neoplasm
35%
Diffuse Large B Cell Lymphoma
34%
Prostate Cancer
34%
Biological Marker
31%
Pancreas Cancer
27%
Pancreas Adenocarcinoma
26%
Acute Myeloid Leukemia
24%
Non Small Cell Lung Cancer
23%
Lung Cancer
22%
Colorectal Cancer
22%
Immune Checkpoint Inhibitor
21%
Progression Free Survival
18%
Bone Metastasis
15%
Pleura Mesothelioma
15%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Minimal Residual Disease
11%
Recurrent Disease
11%
Clinical Trial
11%
Remission
11%
Psychotropic Agent
10%
Immunotherapy
10%
Vincristine
10%
Prostate Specific Membrane Antigen
9%
Fluorine 18
9%
Rectum Cancer
9%
Hodgkin Disease
9%
Case-Control Study
9%
Telomerase
9%
Cancer Staging
8%
Solid Malignant Neoplasm
8%
Prevalence
8%
Rituximab
8%
Secreted Frizzled Related Protein 1
8%
Recurrence Risk
7%
Nivolumab
7%
Hematologic Malignancy
7%
Follicular Lymphoma
7%
Adverse Event
7%
Gemcitabine
7%
Programmed Death 1 Ligand 1
7%
Randomized Controlled Trial
7%
Cancer Recurrence
7%
Prospective Study
7%
Monotherapy
6%
Nonhodgkin Lymphoma
6%
Myelodysplastic Syndrome
6%
Patient Registry
6%
Ipilimumab
6%
Castration Resistant Prostate Cancer
6%
Circulating Tumor DNA
6%
Second Cancer
6%
Gallium 68
6%
High Dose Chemotherapy
6%
Neuroendocrine Tumor
6%
Venetoclax
6%
Sodium Fluoride
6%
Chemoradiation Therapy
6%
microRNA 155
6%
Esophagus Cancer
6%
Myeloproliferative Neoplasm
6%
Liver Cell Carcinoma
6%
Mantle Cell Lymphoma
6%
Prognosis
6%
Multiple Myeloma
5%
Anticarcinogen
5%
Drug Resistance
5%
Glucocorticoid
5%
Hemoglobin A1c
5%
Keyphrases
National Cohort Study
31%
Denmark
26%
Lymphoma Patients
15%
Lymphoma
13%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
Population-based
10%
Prostate Cancer
9%
Colorectal Cancer
9%
Rheumatoid Arthritis
9%
Matched Cohort Study
9%
Risk Factors
8%
PSMA PET-CT
8%
Confidence Interval
7%
Pancreatic Adenocarcinoma
7%
Newly Diagnosed
7%
Danish Population
6%
Hazard Ratio
6%
SFRP1
6%
Gemcitabine
6%
Danish Registers
6%
Register Study
6%
Pancreatic Ductal Adenocarcinoma
6%
Local Recurrence Rate
6%
Recurrent Prostate Cancer
6%
Ga-PSMA
6%
Atrial Fibrillation
6%
Patient Cohort
6%
Fibroblast Activation Protein Inhibitor
6%
18F-sodium Fluoride PET
6%
Second Primary Malignancy
6%
Eosinophilic Esophagitis
6%
Polyautoimmunity
6%
New-onset Diabetes
6%
Systemic Anti-cancer Treatment
6%
Reproduction Pattern
6%
Oncologic Emergency
6%
Exhaled Breath Condensate
6%
Bone Scan Index
6%
Promoter Methylation
6%
Curative Treatment
6%
Haematological Cancer Survivors
6%
Background Population
6%
Chemotherapy-induced Peripheral Neuropathy
6%
Temporal Trends
6%
Prognostic Marker
6%
Lung Cancer Risk
6%
Metabolic Tumor Volume
6%
Malignant Pleural Mesothelioma
6%
Pancreatic Cancer
5%
Overall Survival
5%
Bone Scintigraphy
5%
Follicular Lymphoma
5%
Danish National Patient Registry
5%
Relative Risk
5%
Odds Ratio
5%
Primary Staging
5%